Amy Werremeyer1, Jolene Bostwick2, Carla Cobb3, Tera D Moore4, Susie H Park5, Cristofer Price6, Jerry McKee7. 1. Associate Professor, School of Pharmacy, North Dakota State University, Fargo, North Dakota, amy.werremeyer@ndsu.edu. 2. Clinical Professor and Associate Chair, University of Michigan College of Pharmacy, Ann Arbor, Michigan. 3. Owner and Consultant, Capita Consulting, Billings, Montana. 4. National Pharmacy Benefits Management Program Manager, Clinical Practice Integration and Model Advancement, Clinical Pharmacy Practice Office, Pharmacy Benefits Management Services, US Department of Veterans Affairs, Washington, DC. 5. Associate Professor, School of Pharmacy, University of Southern California, Los Angeles, California. 6. Clinical Pharmacy Program Manager - Mental Health, Providence Veterans Affairs Medical Center, Providence, Rhode Island. 7. CEO and Lead Consultant, Psychopharm Solutions LLC, Morganton, North Carolina.
Abstract
INTRODUCTION: Psychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. A 2015 review highlighted the value of psychiatric pharmacists in improving medication-related outcomes. There is a need to describe areas of expansion and strengthened evidence regarding pharmacist practice and patient care impact in psychiatric and neurologic settings since 2015. METHODS: A systematic search of literature published from January 2014 to June 2019 was conducted. Publications describing patient-level outcome results associated with pharmacist provision of care in a psychiatric/neurologic setting and/or in relation to central nervous system (CNS) medications were included. RESULTS: A total of 64 publications were included. There was significant heterogeneity of published study methods and data, prohibiting meta-analysis. Pharmacists practicing across a wide variety of health care settings with focus on CNS medication management significantly improved patient-level outcomes, such as medication adherence, disease control, and avoidance of hospitalization. The most common practice approach associated with significant improvement in patient-level outcomes was incorporation of psychiatric pharmacist input into the interprofessional health care team. DISCUSSION: Pharmacists who focus on psychiatric and neurologic disease improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Additional studies designed to measure pharmacists' impact on patient-level outcomes are encouraged to strengthen these findings.
INTRODUCTION: Psychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. A 2015 review highlighted the value of psychiatric pharmacists in improving medication-related outcomes. There is a need to describe areas of expansion and strengthened evidence regarding pharmacist practice and patient care impact in psychiatric and neurologic settings since 2015. METHODS: A systematic search of literature published from January 2014 to June 2019 was conducted. Publications describing patient-level outcome results associated with pharmacist provision of care in a psychiatric/neurologic setting and/or in relation to central nervous system (CNS) medications were included. RESULTS: A total of 64 publications were included. There was significant heterogeneity of published study methods and data, prohibiting meta-analysis. Pharmacists practicing across a wide variety of health care settings with focus on CNS medication management significantly improved patient-level outcomes, such as medication adherence, disease control, and avoidance of hospitalization. The most common practice approach associated with significant improvement in patient-level outcomes was incorporation of psychiatric pharmacist input into the interprofessional health care team. DISCUSSION: Pharmacists who focus on psychiatric and neurologic disease improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Additional studies designed to measure pharmacists' impact on patient-level outcomes are encouraged to strengthen these findings.
Authors: Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht Journal: World Psychiatry Date: 2011-02 Impact factor: 49.548
Authors: Shubha Bhat; Miranda E Kroehl; Katy E Trinkley; Zeta Chow; Lauren J Heath; Sarah J Billups; Danielle F Loeb Journal: Popul Health Manag Date: 2017-12-06 Impact factor: 2.459
Authors: J Das-Munshi; M Ashworth; M E Dewey; F Gaughran; S Hull; C Morgan; J Nazroo; I Petersen; P Schofield; R Stewart; G Thornicroft; M J Prince Journal: Diabet Med Date: 2017-01-30 Impact factor: 4.359
Authors: Eveline L van Velthuijsen; Sandra M G Zwakhalen; Evelien Pijpers; Liesbeth I van de Ven; Ton Ambergen; Wubbo J Mulder; Frans R J Verhey; Gertrudis I J M Kempen Journal: Drugs Aging Date: 2018-02 Impact factor: 3.923
Authors: Sara Spinella; Nicole McCune; Rebecca McCarthy; Maria El-Tahch; Jennifer George; Mary Dorritie; Alyssa Ford; Kira Posteraro; Deborah DiNardo Journal: J Gen Intern Med Date: 2022-08-30 Impact factor: 6.473
Authors: Richard J Silvia; Kelly C Lee; Gregory H Payne; Jessica Ho; Carla Cobb; Elayne D Ansara; Clint A Ross Journal: Ment Health Clin Date: 2022-04-14
Authors: Maria Sole Giurin; Marta Paulina Trojniak; Anna Arbo; Marco Carrozzi; Giuseppe Abbracciavento; Lorenzo Monasta; Caterina Zanus Journal: Front Pharmacol Date: 2022-04-12 Impact factor: 5.988